CLEANTECH-FOR-EUROPE
8.7.2021 09:51:11 CEST | Business Wire | Press release
Cleantech for Europe , a new initiative created by Cleantech Group, supported by Breakthrough Energy, today presented its first ‘EU Quarterly Cleantech Briefing ’. The analysis finds that in the first half of this year more than €7 billion of venture capital was invested in cleantech innovation in the European Union (EU). With six months remaining in 2021, this figure has already beaten the previous annual record for Europe, set just last year at €4.7 billion.
In view of this momentum, Cleantech for Europe will bring together top cleantech leaders from VCs, startups, academia, and civil society to build much-needed bridges with policymakers in Brussels and other European capitals. In a first instance, six leading cleantech venture capital firms, regarded as pioneers in financing innovative low-carbon companies, are joining the initiative. Other communities from start-ups, scale-ups, academia and civil society will join the initiative over time to build a future-oriented, technology-savvy group of cleantech leaders from across the EU.
The six “Cleantech for Europe Leaders” are: Beamline Accelerator (Estonia), btov Industrial Tech Fund (Germany), Inven Capital (Czech Republic), Munich Venture Partners (Germany), Rockstart (Netherlands), and SET Ventures (Netherlands). Combined, these firms have invested in more than 150 innovative low-carbon start-ups and scale-ups, including global leaders such as Sonnen in batteries and Sunfire in hydrogen production. For the first time, these firms are coming together to build a collective voice and convey to policymakers and other stakeholders the importance of investing in the next generation of clean technologies.
Despite the fact that EU cleantech investments are booming compared to previous years, the EU Quarterly Cleantech Briefing notes they may still fall short of what is needed to ensure EU start-ups can scale up across the continent. In the past decade, EU companies seeking to scale have often turned toward Asia or North America for larger markets, more abundant funding and ambitious public policies that accelerate their adoption.
“This analysis illustrates the extraordinary progress of the EU’s cleantech ecosystem – and the mountain of urgent work that lies ahead, particularly around helping build an EU policy framework that prioritizes and supports cleantech innovation.” said Ann Mettler, Vice President Europe at Breakthrough Energy, an organization founded by Bill Gates to support the innovations that will lead the world to net-zero emissions.
The release of the investment tracker and the announcement of the Cleantech for Europe initiative come just days before the EU prepares to unveil its highly anticipated “Fit for 55” package of climate legislation, and as most EU member states are finalizing Covid economic recovery plans that the European Commission has stipulated must include strong climate- and clean energy-related components.
The analysis also found: increasing numbers of late-stage deals; major deals of €300 million or more in industries including batteries, electric mobility, shared mobility and the circular economy; and a sharp uptick in the number of deals in the materials and chemicals sector. Sign up for future quarterly briefings here .
The involvement of top venture capital firms in the Cleantech for Europe initiative underscores how important policy is to the success of cleantech innovation.
“The goal of the new initiative is to place cleantech innovation at the center of EU public policy debates in the coming weeks, months and years,” said Jules Besnainou, director at Cleantech Group, a research and consulting company that is helping organize the new group and author the quarterly briefings. “We want the bloc to capitalize on opportunities to build and expand clean industries, ensure a just transition, and mount a stronger response to a climate crisis which grows more urgent by the day.”
“The regulatory framework is critical for success in cleantech. We see it in hydrogen: strong policy moves result in market uptake.” added Ivo Němejc, Vice Chairman of the Board of Directors, Inven Capital
“It is still very hard for EU cleantech start-ups to scale beyond their national borders. If we want to lead the race to net zero, we need to start building continental champions.” said Martin Kröner, Managing Partner, Munich Venture Partners
“The energy transition is a systemic challenge, but also an opportunity for the EU to lead the world on climate innovation while creating high-quality jobs.” added René Savelsberg, Managing Partner and Co-Founder, SET Ventures
“To reach climate leadership, we must improve the funding cycle for EU cleantech. The time to act is now.” said Christian Reitberger, Partner, btov Industrial Tech Fund
“Our success in Estonia proves that efficient cooperation between policy-makers and cleantech leaders is in fact a must for sustainable innovation development.” added Erki Ani, CEO, Beamline Accelerator
Additional venture capital firms are expected to join the group in the coming months.
Specifically, the Cleantech for Europe initiative calls on the EU to:
- Create a demand shock for green solutions. Create sectoral transition plans. Implement a predictable and progressive price on carbon. Accelerate green public procurement.
- Support the creation of at least 10 EU scale-up funds. Increase non-dilutive funding. Leverage public-private instruments such as carbon contracts for difference.
- Support cross-border scaling. Harmonize regulations and standards to allow innovative companies scale from one country to the continent. Develop integrated value chains across all member states.
In unveiling the investment tracker, Cleantech for Europe also announced that it will hold an inaugural Cleantech for Europe Summit on September 8, featuring key leaders from Europe’s venture capital and policy communities. The Summit will be opened by Pascal Canfin, MEP and Chair of the Committee on the Environment, Public Health and Food Safety at the European Parliament. To participate in the Summit, sign up here .
To set up interviews with European venture capitalists and innovators active in the cleantech space, and policy experts, or to get more of the backstory on how and why the Cleantech for Europe initiative was conceived, please contact Jules Besnainou at hello@cleantechforeurope.com
About Cleantech for Europe
Cleantech for Europe is an initiative created by Cleantech Group, supported by Breakthrough Energy and leading EU cleantech investors. Our mission is to help the EU lead the race to net zero while creating long-term industrial competitiveness. We aim to put innovation at the center of the public policy debate and build bridges between the EU’s cleantech community and policymakers in Brussels and member states.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005349/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
